5-溴-2-甲基-1-（苯基磺酰）-1H-吡唑并[2,3-B]吡啶 | 1111638-01-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴-2-甲基-1-（苯基磺酰）-1H-吡唑并[2,3-B]吡啶
• 英文名称: 5-bromo-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 1-(benzenesulfonyl)-5-bromo-2-methylpyrrolo[2,3-b]pyridine
• CAS: 1111638-01-7
• 化学式: C₁₄H₁₁BrN₂O₂S
• 分子量: 351.224
• InChiKey: RTBZYOAMRPSNGO-UHFFFAOYSA-N

物化性质

• 沸点：
  505.1±60.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3
• 危险标志：
  GHS06
• 危险性描述：
  H301
• 危险性防范说明：
  P301 + P310
• 海关编码：
  2933990090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 5-Bromo-2-Methyl-1-(Phenylsulfonyl)-1H-
Pyrrolo[2,3-B]Pyridine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 351,22 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
5-Bromo-2-Methyl-1-(Phenylsulfonyl)-1H-Pyrrolo[2,3-B]Pyridine
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
5-Bromo-2-Methyl-1-(Phenylsulfonyl)-1H-Pyrrolo[2,3-B]Pyridine
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (5-Bromo-2-Methyl-1-(Phenylsulfonyl)-1H-Pyrrolo[2,3-
B]Pyridine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (5-Bromo-2-Methyl-1-(Phenylsulfonyl)-1H-Pyrrolo[2,3-
B]Pyridine)
IATA: Toxic solid, organic, n.o.s. (5-Bromo-2-Methyl-1-(Phenylsulfonyl)-1H-Pyrrolo[2,3-B]Pyridine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H301 Toxic if swallowed.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  5-溴-2-甲基-1-（苯基磺酰）-1H-吡唑并[2,3-B]吡啶 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 以76.9%的产率得到5-溴-2-甲基-1H-吡咯并[2,3-b]吡啶
  参考文献：
  名称：

  1H-吡咯并[2,3- b ]吡啶和1H-吡唑并[3,4- b ]吡啶衍生物作为c-Met抑制剂的设计，合成及生物学评价

  摘要：

  设计，合成了五种新颖的1H-吡咯并[2,3- b ]吡啶或1H-吡唑并[3,4- b ]吡啶衍生物，以亚甲基，硫，亚砜或环丙基为连接基，并对其生物学性质进行了评估。 -碰到和ALK。这些化合物合成方法的发展可能为构建具有单原子连接子的新型7-氮杂吲哚和7-氮杂吲唑衍生物提供重要的参考。体外酶测定和细胞测定表明，化合物9表现出强c-Met激酶抑制作用，IC 50为22.8 nM，中度ALK激酶抑制作用，以及强细胞抑制作用，MKN-45 IC 50为329 nM，EBC-1 IC 50479 nM。为了找到更好的候选化合物，化合物8，9和10已被选择用于进一步优化工具的化合物。

  DOI：

  10.1016/j.bioorg.2016.02.009
• 作为产物：
  描述：

  5-溴-7-氮杂吲哚 在 正丁基锂 、 四丁基溴化铵 、 异丙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 5-溴-2-甲基-1-（苯基磺酰）-1H-吡唑并[2,3-B]吡啶
  参考文献：
  名称：

  [EN] MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES
  [FR] INHIBITEURS DE KINASE DE LIGNAGE MIXTE POUR DES THÉRAPIES POUR LE VIH/SIDA

  摘要：

  揭示了治疗感染逆转录病毒的个体的方法，包括向个体施用有效量的混合谱系激酶抑制剂和抗逆转录病毒药物。此外，还揭示了治疗感染逆转录病毒的个体的方法，包括向个体施用配制成含有表面活性剂的结晶纳米粒子的抗逆转录病毒药物，以及MLK抑制剂。进一步揭示了治疗感染逆转录病毒的个体的方法，包括向个体施用包含抗逆转录病毒和MLK抑制剂的组合物，该组合物配制成含有表面活性剂的结晶纳米粒子。还揭示了包含抗逆转录病毒药物、MLK抑制剂和表面活性剂的组合物，其中该组合物是结晶纳米粒子。还揭示了包含MLK抑制剂与其他药物在纳米粒形式中的组合物，以及其使用方法。

  公开号：

  WO2014085795A1

文献信息

• Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors
  作者：Na Liu、Yanfen Wang、Gongchao Huang、Conghui Ji、Wei Fan、Haitao Li、Ying Cheng、Hongqi Tian

  DOI：10.1016/j.bioorg.2016.02.009

  日期：2016.4

  Five novel 1H-pyrrolo[2,3-b]pyridine or 1H-pyrazolo[3,4-b]pyridine derivatives, with a methylene, sulfur, sulfoxide or cyclopropyl group as a linker, were designed, synthesized and biologically evaluated against c-Met and ALK. The development of these methods of compound synthesis may provide an important reference for the construction of novel 7-azaindole and 7-azaindazole derivatives with a single

  设计，合成了五种新颖的1H-吡咯并[2,3- b ]吡啶或1H-吡唑并[3,4- b ]吡啶衍生物，以亚甲基，硫，亚砜或环丙基为连接基，并对其生物学性质进行了评估。 -碰到和ALK。这些化合物合成方法的发展可能为构建具有单原子连接子的新型7-氮杂吲哚和7-氮杂吲唑衍生物提供重要的参考。体外酶测定和细胞测定表明，化合物9表现出强c-Met激酶抑制作用，IC 50为22.8 nM，中度ALK激酶抑制作用，以及强细胞抑制作用，MKN-45 IC 50为329 nM，EBC-1 IC 50479 nM。为了找到更好的候选化合物，化合物8，9和10已被选择用于进一步优化工具的化合物。
• BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE
  申请人：Gelbard Harris A.

  公开号：US20130203755A1

  公开（公告）日：2013-08-08

  Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

  提供了一些具有抑制激酶活性的化合物，包括混合谱系激酶。还提供了制药组合物、制备这些化合物的方法、合成中间体以及使用这些化合物的方法，可单独使用或与其他治疗药物结合，用于治疗受混合谱系激酶抑制影响的疾病和病况。还提供了抑制混合谱系激酶的方法，用于治疗神经精神障碍。
• Bicyclic heteroaryl kinase inhibitors and methods of use
  申请人：Gelbard Harris A.

  公开号：US08846909B2

  公开（公告）日：2014-09-30

  Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

  提供了一些具有抑制激酶活性的化合物，包括混合谱系激酶。同时还提供了药物组合物、制备该化合物的方法、合成中间体以及使用该化合物的方法，可以独立使用或与其他治疗药物联合使用，用于治疗受混合谱系激酶抑制影响的疾病和病况。同时还提供了抑制混合谱系激酶的方法，用于治疗神经精神障碍。
• MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150297587A1

  公开（公告）日：2015-10-22

  Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.

  本发明涉及治疗感染逆转录病毒的个体的方法，包括向个体施用混合谱系激酶抑制剂和抗逆转录病毒药物的有效剂量。在进一步的方面，本发明涉及治疗感染逆转录病毒的个体的方法，包括向个体施用配制成晶体纳米粒子的抗逆转录病毒药物，该纳米粒子包括表面活性剂和MLK抑制剂。还公开了治疗感染逆转录病毒的个体的方法，包括向个体施用包含抗逆转录病毒和MLK抑制剂的组合物，该组合物配制成晶体纳米粒子，其中包含表面活性剂。此外，还公开了包含抗逆转录病毒药物、MLK抑制剂和表面活性剂的组合物，其中该组合物是晶体纳米粒子。还公开了将MLK抑制剂与其他药物配制成纳米粒子形式的组合物及其使用方法。
• COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION
  申请人：Betta Pharmaceuticals Co., Ltd.

  公开号：EP3719017A2

  公开（公告）日：2020-10-07

  The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.

  本发明涉及一种溴链抑制剂。本发明还提供了包含此类化合物的组合物和制剂，以及使用和制备此类化合物的方法。